Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.
about
Circulating miRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection.The impact of hepatic pressurization on liver shear wave speed estimates in constrained versus unconstrained conditionsSevere adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: A systematic review.Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemiaReal-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis.PRO-C3-levels in patients with HIV/HCV-Co-infection reflect fibrosis stage and degree of portal hypertensionTelaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosisThe VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated CirrhosisTwo IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis.Indications for portal pressure measurement in chronic liver disease.Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients.Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients.Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites.Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis.Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study.von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis.Evaluation of a new balloon occlusion catheter specifically designed for measurement of hepatic venous pressure gradient.The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol
P2860
Q30418874-B6DCE691-B08B-4FCC-9069-83512773FEC4Q30459018-5359C62E-BF3D-4E83-B4C3-4ABFF224EB26Q33406835-08337398-98E2-4757-B257-B506DBA8D756Q33424963-9D0B566C-833A-4E60-84CD-62D5052880FBQ33430833-53E25D61-81FE-4B96-AA71-8A2F866BEC70Q34268818-5B123299-9162-4070-B98E-736E85AC97D9Q35270937-B551DBA9-2148-44E6-9FEE-E86CF8115D97Q35928746-5F6675FC-C13C-49BD-8201-4177A16A623BQ35995534-346A513C-15E3-4BA8-BD05-7C454D259678Q36224697-A587D18F-FD58-4FA4-ADF4-4E6E6F5B0206Q38027225-B49FBDF5-37A9-4CAE-A2F6-5E0A1A6DB817Q40399465-74DFDCF9-F798-4AF9-9C0D-F021E5A65FDFQ40706073-B59FB114-1BBF-474A-AAC4-BED70EF1C787Q41508212-D9A155B2-466F-49EE-9E04-A75C982B9D22Q41582122-728F01CD-99AB-41D2-B6D7-16C6B4715AC2Q42249410-FB6B546B-E23E-46D1-B848-BDB8BB227B2CQ50590574-08F0B630-50A2-46DC-B176-50408D6B011CQ51344051-2BACB760-FB73-4719-87F7-780C8BC6EE1FQ53339536-517DC9CE-F1CC-4298-A733-7C0664AF354FQ54342105-71D65098-A653-4C3E-8F95-9F1769939E1AQ57168135-9F0C7AF3-9B8E-4917-BBC5-766C6256EA75
P2860
Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Portal pressure predicts outco ...... h hepatitis C virus infection.
@ast
Portal pressure predicts outco ...... h hepatitis C virus infection.
@en
type
label
Portal pressure predicts outco ...... h hepatitis C virus infection.
@ast
Portal pressure predicts outco ...... h hepatitis C virus infection.
@en
prefLabel
Portal pressure predicts outco ...... h hepatitis C virus infection.
@ast
Portal pressure predicts outco ...... h hepatitis C virus infection.
@en
P2093
P50
P1476
Portal pressure predicts outco ...... h hepatitis C virus infection.
@en
P2093
Alfred Gangl
Arnulf Ferlitsch
Berit Anna Payer
Harald Hofer
Karoline Rutter
Michael Trauner
Peter Ferenci
Sandra Beinhardt
P304
P356
10.1016/J.CGH.2011.03.002
P407
P577
2011-03-10T00:00:00Z